Louis Moore Bacon's BCRX Position Overview
Louis Moore Bacon (via Moore Capital Management, Lp) currently holds 848,336 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $8.48 M, representing 0.13% of the portfolio. First purchased in 2022-Q4, this short-term holding has been held for 3 quarters.
Based on 13F filings, Louis Moore Bacon has maintained this position in BCRX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 848,336 shares. Largest reduction occurred in Q1 2023, reducing 65,000 shares.
Analysis based on 13F filings available since 2013 Q2
Louis Moore Bacon's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Louis Moore Bacon
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +848,336 | New Buy | 848,336 | $10.00 |
| Q1 2023 | -65,000 | Sold Out | 0 | $0.00 |
| Q4 2022 | +65,000 | New Buy | 65,000 | $11.48 |
Louis Moore Bacon's BioCryst Pharmaceuticals Investment FAQs
Louis Moore Bacon first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q4 2022, acquiring 65,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Louis Moore Bacon has held BioCryst Pharmaceuticals, Inc. (BCRX) for 3 quarters since Q4 2022.
Louis Moore Bacon's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q2 2026, adding 848,336 shares worth $8.48 M.
According to the latest 13F filing for Q2 2026, Louis Moore Bacon's firm, Moore Capital Management, Lp, owns 848,336 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $8.48 M.
As of the Q2 2026 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.13% of Louis Moore Bacon's publicly disclosed stock portfolio, making it one of their key holdings.
Louis Moore Bacon's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 848,336 shares, as reported at the end of Q2 2026.